Document Detail

A novel formulation of an ophthalmic beta-adrenoceptor antagonist.
MedLine Citation:
PMID:  1588458     Owner:  NLM     Status:  MEDLINE    
To minimize ocular discomfort while maintaining efficacy, a delivery system for a topical cardioselective beta-adrenoceptor antagonist, betaxolol was developed. Betaxolol was formulated at 0.25% concentration in a cationic exchange resin, as a suspension. A polyacrylic acid polymer was added to increase viscosity and to increase residence time in the cul-de-sac. No significant settling was observed throughout a four-week observation period. Thus, resuspension of the formulation by frequent shaking was not required for uniformity. In rabbits, the ocular bioavailability of 0.25% betaxolol suspension was equivalent to that of 0.5% betaxolol solution.
R N Weinreb; R Jani
Related Documents :
6459778 - Sequential hydrolysis of hyaluronate by beta-glucuronidase and beta-n-acetylhexosaminid...
9023648 - Potential effects of amoxycillin/clavulanic acid and ticarcillin/clavulanic acid on hum...
11472118 - Stereocontrolled asymmetric synthesis of alpha-hydroxy-beta-amino acids. a stereodiverg...
2979728 - Thioacylating intermediates as metabolites of s-(1,2-dichlorovinyl)-l-cysteine and s-(1...
14556798 - Synthesis, molecular modeling and biological evaluation of aza-proline and aza-pipecoli...
10408758 - The role of the carnitine system in peroxisomal fatty acid oxidation.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of parenteral science and technology : a publication of the Parenteral Drug Association     Volume:  46     ISSN:  0279-7976     ISO Abbreviation:  J Parenter Sci Technol     Publication Date:    1992 Mar-Apr
Date Detail:
Created Date:  1992-06-22     Completed Date:  1992-06-22     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  8103145     Medline TA:  J Parenter Sci Technol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  51-3     Citation Subset:  IM    
Department of Ophthalmology, School of Medicine, University of California, San Diego 92093.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Betaxolol / administration & dosage*
Ophthalmic Solutions
Reg. No./Substance:
0/Ophthalmic Solutions; 0/Suspensions; 63659-18-7/Betaxolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Toxicity potential of compounds found in parenteral solutions with rubber stoppers.
Next Document:  Lyophilization closures for protein based drugs.